Skip to main content
Marvel Biosciences Corp. logo

Marvel Biosciences Corp. — Investor Relations & Filings

Ticker · MRVL TSXV Professional, scientific and technical activities
Open in API
Filings indexed 203 across all filing types
Latest filing 2025-05-13 Capital/Financing Update
Country CA Canada
Listing TSXV MRVL

About Marvel Biosciences Corp.

https://marvelbiotechnology.com/

Marvel Biosciences Corp. is a pre-clinical stage biotechnology company specializing in the discovery and development of transformative treatments for complex neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome, and Fragile X Syndrome. The company's core strategy involves chemical innovation to create synthetic derivatives of existing approved molecules. This drug redevelopment approach leverages established mechanisms to accelerate development and reduce risk. Its lead candidate, MB-204, is a patented synthetic derivative that has demonstrated preclinical efficacy across these target indications and is currently advancing toward first-in-human studies.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the closing of a non‐brokered private placement including details on units issued, warrant terms, and gross proceeds. This is a fundraising/capital structure update, matching the “Capital/Financing Update” category.
2025-05-13 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing the closing of the second tranche of a non-brokered private placement, detailing unit issuance, warrant terms, finders’ fees, use of proceeds, and regulatory approvals. This clearly constitutes an update on the company’s fundraising activities, matching the Capital/Financing Update category.
2025-05-02 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 1% confidence The document is the full Form 45-106F1 “Report of Exempt Distribution,” a Canadian securities regulatory form providing detailed issuer, distribution, and compensation information. It is neither an earnings release nor a management discussion, nor any of the specialized categories like M&A, dividends, or AGM materials. It represents a mandatory regulatory filing under Canadian securities rules. Thus it falls under the generic “Regulatory Filings” category (Code: RNS).
2025-04-17 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing that Marvel Biosciences will present at a scientific meeting. It is not a financial results release, regulatory form, shareholder vote, or capital notice. It does not contain an attached formal report or an investor slide deck, but is a general announcement to the market. Therefore it falls under the fallback category "Regulatory Filings" (RNS).
2025-04-16 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a certification form (Form 52-109FV2) by the CFO attesting to the accuracy and fair presentation of interim financial filings under Canadian NI 52-109. It is not the interim report itself, nor an MD&A, earnings release, or investor presentation, but a regulatory compliance certificate. This falls under general regulatory filings (RNS).
2025-04-01 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 “Certification of Interim Filings” by the CEO, confirming review and fair presentation of the interim financial report and interim MD&A for the period ended January 31, 2025. This is a regulatory certificate rather than the interim report itself, and it does not fit into any specific category (e.g., IR for the report or MDA for MD&A). It is therefore best classified under the fallback “Regulatory Filings” category (RNS).
2025-04-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.